Carvedilol and its new analogs suppress arrhythmogenic store overload–induced Ca2+ release
- 10 July 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 17 (8), 1003-1009
- https://doi.org/10.1038/nm.2406
Abstract
Carvedilol is one of the most effective beta blockers for preventing ventricular tachyarrhythmias in heart failure, but the mechanisms underlying its favorable antiarrhythmic benefits remain unclear. Spontaneous Ca2+ waves, also called store overload–induced Ca2+ release (SOICR), evoke ventricular tachyarrhythmias in individuals with heart failure. Here we show that carvedilol is the only beta blocker tested that effectively suppresses SOICR by directly reducing the open duration of the cardiac ryanodine receptor (RyR2). This unique anti-SOICR activity of carvedilol, combined with its beta-blocking activity, probably contributes to its favorable antiarrhythmic effect. To enable optimal titration of carvedilol's actions as a beta blocker and as a suppressor of SOICR separately, we developed a new SOICR-inhibiting, minimally beta-blocking carvedilol analog, VK-II-86. VK-II-86 prevented stress-induced ventricular tachyarrhythmias in RyR2-mutant mice and did so more effectively when combined with either of the selective beta blockers metoprolol or bisoprolol. Combining SOICR inhibition with optimal beta blockade has the potential to provide antiarrhythmic therapy that can be tailored to individual patients.Keywords
This publication has 56 references indexed in Scilit:
- Inhibition of Cardiac Ca 2+ Release Channels (RyR2) Determines Efficacy of Class I Antiarrhythmic Drugs in Catecholaminergic Polymorphic Ventricular TachycardiaCirculation: Arrhythmia and Electrophysiology, 2011
- Catecholaminergic Polymorphic Ventricular Tachycardia Is Caused by Mutation-Linked Defective Conformational Regulation of the Ryanodine ReceptorCirculation Research, 2010
- Local control of Ca2+-induced Ca2+ release in mouse sinoatrial node cellsJournal of Molecular and Cellular Cardiology, 2009
- Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark massJournal of Molecular and Cellular Cardiology, 2009
- Arrhythmogenic consequences of intracellular calcium wavesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humansNature Medicine, 2009
- Arrhythmogenic Mechanisms in a Mouse Model of Catecholaminergic Polymorphic Ventricular TachycardiaCirculation Research, 2007
- K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 associationBiochemical Journal, 2007
- Atherosclerosis and Oxidant Stress: The End of the Road for Antioxidant Vitamin Treatment?Cardiovascular Drugs and Therapy, 2007
- Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathyProceedings of the National Academy of Sciences of the United States of America, 2006